window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'UA-48293608-1');
Logo-bi
Bioimpacts. 2025;15: 33007 | Published on: 2025 Nov 10. doi: 10.34172/bi.33007
PMID: 41322392        PMCID: PMC12663746

Editorial

An efficacious opportunity for diagnosis and treatment of cancers: Radiolabeled fibroblast activation protein (FAP) inhibitors

Nasim Vahidfar 1 ORCID, Ayuob Aghanejad 2,3 * ORCID

Cited by CrossRef: 0

1- Talia M, Scordamaglia D, Gianì F, Cirillo F, Panza S, Occhiuzzi M, Mondino A, Silvestri F, Zicarelli A, Meliti C, Di Dio M, Grande F, Malaguarnera R, Paolino D, Maggiolini M, De Francesco E, Lappano R. Molecular advancements in targeting fibroblast activation protein (FAP) in cancer therapies. Expert Opinion on Therapeutic Targets. 2026;:1 [Crossref]

Poster

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate (2025): 19% 
Publication fee: Free of charge

Indexing/Abstracting Info
PubMed; PubMed Central; Scopus; Science Citation Index Expanded; Google Scholar;   SJR; Essential Science Indicators; Embase; EBSCOhost; CAS: DOAJ: SHERPA/RoMEO
Member of   
Follower of ICMJE
Permission: CC BY-NC